US 20210300991A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0300991 A1**

Grinberg et al. (43) **Pub. Date: Sep. 30, 2021**

(54) **ENDOGLIN POLYPEPTIDES AND USES THEREOF**

(71) Applicant: **Acceleron Pharma Inc.**, Cambridge, MA (US)

(72) Inventors: **Asya Grinberg**, Lexington, MA (US); **Roselyne Castonguay**, Watertown, MA (US); **Eric Werner**, Milton, MA (US); **Ravindra Kumar**, Acton, MA (US)

(73) Assignee: **Acceleron Pharma Inc.**, Cambridge, MA (US)

(21) Appl. No.: **17/205,573**

(22) Filed: **Mar. 18, 2021**

Related U.S. Application Data

(60) Continuation of application No. 15/908,644, filed on Feb. 28, 2018, now Pat. No. 10,981,972, which is a division of application No. 14/112,620, filed on Dec. 31, 2013, now Pat. No. 9,932,386, filed as application No. PCT/US12/34295 on Apr. 19, 2012.

(60) Provisional application No. 61/477,585, filed on Apr. 20, 2011.

Publication Classification

(51) **Int. Cl.**
C07K 14/705 (2006.01)

(52) **U.S. Cl.**
CPC ***C07K 14/70596*** (2013.01); *A61K 38/00* (2013.01)

(57) **ABSTRACT**

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

Specification includes a Sequence Listing.